Insys Therapeutics, Inc. (NASDAQ:INSY)

On August 11, 2014, we released the following:

As we have been closely following the hot cannabis industry, we noticed two companies that are working to develop competing Cannabidiol (“CBD”) compounds to treat epilepsy in children – INSYS Therapeutics, Inc. (NASDAQ:INSY) and GW Pharmaceuticals plc (NASDAQ:GWPH). INSY is our bullish call that has been quietly making progress (while insiders buy) without the fanfare and GWPH, our bearish call that in our opinion is making fanfare without properly telegraphing the risks that it faces for its CBD to reach the market (while insiders sell).

• INSYS Therapeutics – go long the substance overhype
• GW Pharmaceuticals – sell the promotional hype

We rate GWPH a SELL with around 40% downside, and INSY a BUY with more than 200% upside potential.

Please go here to see our full article.